X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE ASTRAZENECA PHARMA TTK HEALTHCARE/
ASTRAZENECA PHARMA
 
P/E (TTM) x 19.1 102.7 18.6% View Chart
P/BV x 4.9 28.6 17.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 TTK HEALTHCARE   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
ASTRAZENECA PHARMA
Mar-14
TTK HEALTHCARE/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6631,285 51.6%   
Low Rs399634 62.9%   
Sales per share (Unadj.) Rs535.6189.6 282.5%  
Earnings per share (Unadj.) Rs15.9-0.2 -7,832.0%  
Cash flow per share (Unadj.) Rs20.03.8 520.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs137.668.6 200.5%  
Shares outstanding (eoy) m7.7725.00 31.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.05.1 19.6%   
Avg P/E ratio x33.3-4,712.7 -0.7%  
P/CF ratio (eoy) x26.5249.6 10.6%  
Price / Book Value ratio x3.914.0 27.6%  
Dividend payout %25.10-   
Avg Mkt Cap Rs m4,12723,988 17.2%   
No. of employees `0001.71.6 109.6%   
Total wages/salary Rs m6071,605 37.8%   
Avg. sales/employee Rs Th2,436.73,040.2 80.1%   
Avg. wages/employee Rs Th355.21,029.2 34.5%   
Avg. net profit/employee Rs Th72.5-3.3 -2,221.8%   
INCOME DATA
Net Sales Rs m4,1624,740 87.8%  
Other income Rs m6192 66.4%   
Total revenues Rs m4,2234,832 87.4%   
Gross profit Rs m197-130 -151.8%  
Depreciation Rs m32101 31.3%   
Interest Rs m300-   
Profit before tax Rs m197-139 -141.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m735 1,430.3%   
Profit after tax Rs m124-5 -2,434.2%  
Gross profit margin %4.7-2.7 -172.9%  
Effective tax rate %37.0-3.7 -1,010.0%   
Net profit margin %3.0-0.1 -2,772.2%  
BALANCE SHEET DATA
Current assets Rs m1,6292,726 59.7%   
Current liabilities Rs m1,0582,435 43.4%   
Net working cap to sales %13.76.1 223.1%  
Current ratio x1.51.1 137.5%  
Inventory Days Days3074 40.4%  
Debtors Days Days3441 82.4%  
Net fixed assets Rs m5561,035 53.7%   
Share capital Rs m7850 155.4%   
"Free" reserves Rs m878942 93.2%   
Net worth Rs m1,0691,716 62.3%   
Long term debt Rs m1590-   
Total assets Rs m2,3994,156 57.7%  
Interest coverage x7.6NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x1.71.1 152.1%   
Return on assets %6.4-0.1 -5,233.7%  
Return on equity %11.6-0.3 -3,906.4%  
Return on capital %18.50-  
Exports to sales %0.85.7 13.9%   
Imports to sales %1.46.5 21.7%   
Exports (fob) Rs m33270 12.2%   
Imports (cif) Rs m58306 19.0%   
Fx inflow Rs m33375 8.8%   
Fx outflow Rs m63470 13.4%   
Net fx Rs m-30-96 31.7%   
CASH FLOW
From Operations Rs m127-8 -1,563.0%  
From Investments Rs m-146-146 100.2%  
From Financial Activity Rs m22862 2.5%  
Net Cashflow Rs m3709 0.4%  

Share Holding

Indian Promoters % 65.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 5.2 15.7 33.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 9.1 283.5%  
Shareholders   12,723 12,856 99.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare TTK HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Higher, Oil Prices, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed volatility during closing hours yesterday and ended their day marginally higher.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 60.1% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, TTK HEALTHCARE has posted a net profit of Rs 49 m (down 60.1% YoY). Sales on the other hand came in at Rs 1 bn (up 2.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

Sensex Nearing All-Time Highs: Stocks to Buy in this Rally(Profit Hunter)

Mar 14, 2019

The BSE Sensex is heating up. In just a few days, the benchmark index is up 3%. Is this rally sustainable? Richa finds out...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Mar 20, 2019 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE 5-YR ANALYSIS

COMPARE TTK HEALTHCARE WITH

MARKET STATS